5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials. (April 2018) - Lerebours, F.; Pulido, M.; Fourme, E.; Debled, M.; Becette, V.; Bonnefoi, H.; Rivera, S.; Mac Grogan, G.; Mouret-Reynier, M.A.; Tunon de Lara, C.; Pierga, J.Y.; Breton-Callu, C.; et al.